查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594477

神經病變疼痛治療​​市場：按疼痛類型、適應症、治療方法、分銷管道和最終用戶分類 - 2025-2030 年全球預測

Neuropathy Pain Treatment Market by Pain Type, Indication, Treatment, Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年神經病變疼痛治療​​市值為77.4億美元，預計2024年將達到85.9億美元，複合年成長率為11.53%，2030年將達到166.1億美元。

神經病變疼痛治療​​包括旨在減輕與神經病變疼痛相關的不適的治療方法和藥物，神經性疼痛通常是由多種原因引起的神經損傷引起的，包括糖尿病、化療和身體損傷。神經病變疼痛的慢性和使人衰弱的性質強調了這種治療的必要性，它對生活品質有重大影響，需要有效的管理策略。神經病變疼痛的治療範圍從藥物、醫療設備到針灸和生活方式改變等替代療法。最終用途主要包括醫院和門診診所等醫療機構，以及為尋求便利的慢性疾病患者提供的居家照護環境。

主要市場統計
基準年[2023] 77.4億美元
預測年份 [2024] 85.9億美元
預測年份 [2030] 166.1億美元
複合年成長率（%） 11.53%

糖尿病和癌症盛行率的增加、老年人口的增加以及對神經病變疾病和可用治療方法的認知不斷增強，極大地推動了市場成長。藥物輸送系統的技術進步和新型疼痛管理設備的開發將進一步支持市場擴張。此外，個人化醫療和人工智慧的整合可以實現更好的診斷和個人化治療，有機會顯著改善患者的治療效果。然而，市場開拓受到藥物開發成本高、監管核准嚴格以及長期使用神經病變藥物相關副作用風險等挑戰的阻礙。

該領域的創新應集中於開發非成癮性和更有效的鎮痛藥物以及尋找神經保護劑以預防神經病變疾病的發作和進展。對神經病理性疼痛的遺傳基礎的研究也可能導致標靶治療的突破。在持續的技術創新和研發投入的推動下，市場競爭激烈。鼓勵公司優先考慮與研究機構建立夥伴關係和合作，以推進藥物發現，並參與以患者為中心的產品開發，以有效滿足不斷變化的需求。

市場動態：揭示快速發展的神經病變疼痛治療​​市場的關鍵市場洞察

供需的動態交互作用正在改變神經病變疼痛治療​​市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 神經病變疼痛患者數量不斷增加
    • 全球醫療保健支出增加
    • 神經病變疼痛緩解劑和非處方產品的增加
  • 市場限制因素
    • 對可用治療方案缺乏認知
  • 市場機會
    • 介紹新的疼痛治療方法
    • 專注於安寧療護的計劃和舉措
  • 市場挑戰
    • 確定患者神經病變疼痛的適當治療方法的複雜性

波特的五力：駕馭神經病變疼痛治療​​市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解神經病變疼痛治療​​市場的外部影響

外部宏觀環境因素在塑造神經病變疼痛治療​​市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解神經病變疼痛治療​​市場的競爭格局

對神經病變疼痛治療​​市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣神經病變疼痛治療​​市場供應商的績效評估

FPNV 定位矩陣是評估神經病變疼痛治療​​市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了神經病變疼痛治療​​市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對神經病變疼痛治療​​市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人群中神經病變疼痛的增加
      • 全球醫療保健成本上升
      • 神經病變疼痛緩解藥物和非處方藥的增加
    • 抑制因素
      • 對可用治療方案的認知有限
    • 機會
      • 介紹新的疼痛治療替代方案
      • 專注於安寧療護的計劃和舉措
    • 任務
      • 確定患者神經病變疼痛的適當治療方法的複雜性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依疼痛類型分類的神經病變疼痛治療​​市場

  • 尾骨疼痛
  • 絞窄性神經病變
  • 腳痛
  • 周邊神經神經病變
  • 幻肢神經病變
  • 帶狀皰疹後遺症神經痛(PHN)
  • 神經病變
  • 三叉神經痛

第7章神經病變疼痛治療​​市場（按適應症）

  • 化療引起的周邊神經病變
  • 糖尿病神經病變
  • 脊椎狹窄

第8章神經病變疼痛治療​​市場（依治療）

  • 藥品
    • 抗憂鬱症的類型
      • 血清素去甲腎上腺素
      • 三環抗憂鬱藥物
    • 藥品類型
    • 多模態治療
    • 非類固醇抗發炎藥類型
      • Ibuprofen
      • 萘普生
  • 治療

第9章神經病變疼痛治療​​市場：按分銷管道

  • 網路藥房
  • 零售藥局/藥局

第 10 章神經病變疼痛治療​​市場：依最終使用者分類

  • 診所
  • 醫院

第11章美洲神經病變疼痛治療​​市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區神經病變疼痛治療​​市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的神經病變疼痛治療​​市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Assertio Holdings, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Biogen Inc.
  • Bristol Myers Squibb Company
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson and Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
Product Code: MRR-957C47F9180B

The Neuropathy Pain Treatment Market was valued at USD 7.74 billion in 2023, expected to reach USD 8.59 billion in 2024, and is projected to grow at a CAGR of 11.53%, to USD 16.61 billion by 2030.

Neuropathy pain treatment encompasses therapies and medications aimed at alleviating the discomfort associated with neuropathic pain, a condition often resulting from nerve damage due to various causes like diabetes, chemotherapy, or physical injury. The necessity of such treatments is underscored by the chronic and debilitating nature of neuropathic pain, which can significantly impact quality of life and necessitates effective management strategies. The application scope of neuropathy pain treatment spans across pharmaceuticals, medical devices, and alternative therapies such as acupuncture and lifestyle modifications. End-use predominantly involves healthcare facilities like hospitals and outpatient clinics, alongside home care settings for chronic sufferers seeking convenience.

KEY MARKET STATISTICS
Base Year [2023] USD 7.74 billion
Estimated Year [2024] USD 8.59 billion
Forecast Year [2030] USD 16.61 billion
CAGR (%) 11.53%

The market's growth is largely propelled by the increasing prevalence of diabetes and cancer, rising geriatric population, and the escalating awareness about neuropathic conditions and available treatments. Technological advancements in drug delivery systems and the development of novel pain management devices further fuel market expansion. Moreover, there are opportunities in personalized medicine and the integration of artificial intelligence for better diagnosis and treatment personalization, which can significantly elevate patient outcomes. Nonetheless, market growth is challenged by factors like high drug development costs, stringent regulatory approvals, and the risk of side effects associated with long-term usage of neuropathic medications.

Innovation in this sector should focus on developing non-addictive and more effective analgesics, as well as exploring neuroprotective agents that can prevent the onset or progression of neuropathic damage. Researching the genetic basis of neuropathic pain could also lead to breakthroughs in targeted therapy. The nature of the neuropathy pain treatment market is highly competitive, driven by continuous innovation and R&D investments. Companies are recommended to prioritize partnerships and collaborations with research institutions to advance drug discovery and to engage in patient-centric product development to meet evolving demands efficiently.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neuropathy Pain Treatment Market

The Neuropathy Pain Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in neuropathic pain among population
    • Increasing global healthcare expenditure
    • Growing number of neuropathic pain relievers and over-the-counter products
  • Market Restraints
    • Limited awareness of available treatment options
  • Market Opportunities
    • Introduction of novel pain treatment alternatives
    • Programs and initiatives focusing on palliative care
  • Market Challenges
    • Complexity in identifying the treatment suitable for neuropathic pains in a patient

Porter's Five Forces: A Strategic Tool for Navigating the Neuropathy Pain Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neuropathy Pain Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neuropathy Pain Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neuropathy Pain Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neuropathy Pain Treatment Market

A detailed market share analysis in the Neuropathy Pain Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neuropathy Pain Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neuropathy Pain Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neuropathy Pain Treatment Market

A strategic analysis of the Neuropathy Pain Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neuropathy Pain Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Assertio Holdings, Inc., Astellas Pharma Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Baxter International Inc., Biogen Inc., Bristol Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, GlaxoSmithKline PLC, Johnson and Johnson Services, Inc., Novartis AG, Pfizer Inc., and Sun Pharmaceutical Industries Limited.

Market Segmentation & Coverage

This research report categorizes the Neuropathy Pain Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Pain Type, market is studied across Coccydynia, Entrapment Neuropathy, Foot Pain, Peripheral Neuropathy, Phantom Limb Neuropathy, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, and Trigeminal Neuralgia.
  • Based on Indication, market is studied across Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy, and Spinal Stenosis.
  • Based on Treatment, market is studied across Drugs and Therapy. The Drugs is further studied across Antidepressant Drugs Type, Medication Type, Multimodal Therapy, and NSAIDs Type. The Antidepressant Drugs Type is further studied across Serotonin Noradrenaline and Tricyclic Antidepressants. The NSAIDs Type is further studied across Ibuprofen and Naproxen.
  • Based on Distribution Channel, market is studied across Online Pharmacies and Retail Pharmacies & Drug Stores.
  • Based on End-User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in neuropathic pain among population
      • 5.1.1.2. Increasing global healthcare expenditure
      • 5.1.1.3. Growing number of neuropathic pain relievers and over-the-counter products
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness of available treatment options
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of novel pain treatment alternatives
      • 5.1.3.2. Programs and initiatives focusing on palliative care
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in identifying the treatment suitable for neuropathic pains in a patient
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neuropathy Pain Treatment Market, by Pain Type

  • 6.1. Introduction
  • 6.2. Coccydynia
  • 6.3. Entrapment Neuropathy
  • 6.4. Foot Pain
  • 6.5. Peripheral Neuropathy
  • 6.6. Phantom Limb Neuropathy
  • 6.7. Post Herpetic Neuralgia (PHN)
  • 6.8. Post Traumatic Neuropathy
  • 6.9. Trigeminal Neuralgia

7. Neuropathy Pain Treatment Market, by Indication

  • 7.1. Introduction
  • 7.2. Chemotherapy-Induced Peripheral Neuropathy
  • 7.3. Diabetic Neuropathy
  • 7.4. Spinal Stenosis

8. Neuropathy Pain Treatment Market, by Treatment

  • 8.1. Introduction
  • 8.2. Drugs
    • 8.2.1. Antidepressant Drugs Type
      • 8.2.1.1. Serotonin Noradrenaline
      • 8.2.1.2. Tricyclic Antidepressants
    • 8.2.2. Medication Type
    • 8.2.3. Multimodal Therapy
    • 8.2.4. NSAIDs Type
      • 8.2.4.1. Ibuprofen
      • 8.2.4.2. Naproxen
  • 8.3. Therapy

9. Neuropathy Pain Treatment Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Online Pharmacies
  • 9.3. Retail Pharmacies & Drug Stores

10. Neuropathy Pain Treatment Market, by End-User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Hospitals

11. Americas Neuropathy Pain Treatment Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Neuropathy Pain Treatment Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Neuropathy Pain Treatment Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Assertio Holdings, Inc.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Aurobindo Pharma Limited
  • 6. Baxter International Inc.
  • 7. Biogen Inc.
  • 8. Bristol Myers Squibb Company
  • 9. Dr. Reddy's Laboratories Ltd.
  • 10. Eli Lilly and Company
  • 11. GlaxoSmithKline PLC
  • 12. Johnson and Johnson Services, Inc.
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Sun Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. NEUROPATHY PAIN TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. NEUROPATHY PAIN TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. NEUROPATHY PAIN TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. NEUROPATHY PAIN TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEUROPATHY PAIN TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEUROPATHY PAIN TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COCCYDYNIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ENTRAPMENT NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY FOOT PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PERIPHERAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PHANTOM LIMB NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY POST HERPETIC NEURALGIA (PHN), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY POST TRAUMATIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SPINAL STENOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SEROTONIN NORADRENALINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY MEDICATION TYPE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY MULTIMODAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 324. SPAIN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 20